Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
Date:8/12/2008

MOUNTAIN VIEW, Calif., Aug. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2008.

The net loss for the second quarter ended June 30, 2008 was $16.5 million compared with $8.7 million during the same period in 2007. The net loss for the first six months of 2008 was $30.8 million compared to $15.3 million for the first six months of 2007. As of June 30, 2008, MAP Pharmaceuticals had cash, cash equivalents and short-term investments of $76.2 million.

2008 Year-to-date accomplishments

-- Clinical development

-- Initiated a Phase 3 clinical program to evaluate UDB for the

potential treatment of pediatric asthma.

-- Initiated a Phase 3 clinical program to evaluate MAP0004 for the

potential treatment of migraine, pursuant to a Special Protocol

Assessment with the U.S. Food and Drug Administration.

-- Announced positive results from a pharmacokinetic clinical trial

of UDB, demonstrating lower systemic drug exposure when compared

to the currently marketed conventional nebulized budesonide.

-- Demonstrated positive results from a Phase 2a clinical study

evaluating MAP0005 for the potential treatment of asthma and

chronic obstructive pulmonary disease (COPD).

-- Peer-reviewed presentations

-- Published positive results from a Phase 2 study evaluating the

safety, tolerability and pharmacokinetics of MAP0004 in adult

asthmatics in Current Medical Research and Opinion.

-- Published positive results from a Phase 1 study evaluating the'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
2. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
3. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
4. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
5. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
6. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
7. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
8. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
9. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
10. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily ... FDA clearance for results that last for two years, the longest of any cellulite ... who are looking for a long-lasting, effective solution for their cellulite, according to Dr. ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint ... grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine in a ... for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods ...
(Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s largest ... Work in Healthcare by Modern Healthcare and will be honored at an awards ... eighth year, the Best Places to Work in Healthcare program recognizes outstanding employers in ...
(Date:8/28/2015)... ... August 28, 2015 , ... SmartPractice Calendars afford ... with practice contact information and logos, Calendars stand alone as functional brand-building ... into seasonal mailings, thank you and welcome communications, and to complement statements and ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... collaboration with coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® ... Thermal Flavor Extraction™ technology, which delivers a variety of sizes and styles while ...
Breaking Medicine News(10 mins):Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3
... may potentially play a role in the maintenance of ... a recent issue of Nutrition in Clinical Care. The ... on risk factors for heart disease. Several studies suggest ... and blood pressure. It may also help keep blood ...
... doses of painkillers to ease the agony of terminally ... have criticized the practice, comparing it to euthanasia, but ... receiving higher doses of drugs such as morphine live ... , ,In research published in The Lancet medical journal, ...
... children with autism. Antibiotcs seem to treat or prevent the ... every 150 children is affected by autism. Currently there are ... Hospital in Chicago found that a subset of patients with ... can be helped by antibiotic vancomycin. ,Interestingly the ...
... The discovery of the gene associated with the inherited form ... of Columbia University and James A. Knowles of the Columbia ... study, funded in part by the National Heart, Lung, and ... in the September issue of the American Journal of Human ...
... when given to children with diarrhea caused by ... increased risk of developing a serious condition known ... website of The New England Journal of Medicine ... children after a gastrointestinal infection, begins with vomiting ...
... and Blood Institute (NHLBI) and the National High Blood ... to treat Hypertension.,Control of systolic blood pressure is as ... a crucial message for health care providers, patients, and ... systolic blood pressure to less than 140 mm Hg ...
Cached Medicine News:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
(Date:8/28/2015)... 28, 2015  IP Shakti, LLC, today announced that it ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... new corporate identity signifies our transformation into a company focused ... platform for patent claim validity." ... proprietary AIA Shield™ platform, the Company commenced a corporate re-branding ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... RATON, Fla., Sept. 15 Watermark Medical , ... the sleep-disordered breathing market, has expanded the market reach ... strategic alliances with three leading sleep solution providers in ... SleepQuest , a national provider of comprehensive sleep apnea ...
... Sept. 15 ViroPharma Incorporated (Nasdaq: VPHM ... Phase 1 study of VP20621 (non-toxigenic Clostridium difficile ... Clostridium difficile infections (CDI), a common and dangerous ... of antibiotic medications.  VP20621 contains the spores of a ...
Cached Medicine Technology:Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 2Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 3Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 4ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 2ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 3ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 4ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 5ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 6
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... The Newmarket Laboratories RPR kits ... mixture of lipid antigens, which will ... serum or plasma. The particles are ... to eliminate non - specific reactions. ...
... a quality assurance reagent in assays detecting ... (TOXO IgG and TOXO IgM), IgG and ... and rubella IgM), IgG and IgM antibodies ... and IgG antibodies to herpes simplex virus ...
... The Diamedix Immunosimplicity (Is) Rubella ... procedure,intended for the qualitative and quantitative ... test can be performed either manually ... Automated EIA Processor. The results are ...
Medicine Products: